Related Experiment Videos

The new varicella vaccine: efficacy, safety, and administration

L Sparks1, C Russell

  • 1Jewish Hospital College of Nursing and Allied Health, St. Louis, MO 63110, USA.

Insights

The varicella vaccine (Varivax) is safe and effective for children, offering 95-100% immunity for at least 10 years. This review covers its clinical trials, risks, benefits, and administration guidelines for nurses.

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • The U.S. Food and Drug Administration (FDA) has approved the varicella vaccine (Varivax) for pediatric use.
  • Over 11,000 children, both healthy and immunocompromised, have received the vaccine since 1979.
  • Varivax demonstrates high efficacy and a favorable safety profile.

Purpose of the Study:

  • To review the existing research literature on clinical trials of the Varivax vaccine.
  • To analyze the risks, benefits, and projected costs associated with varicella vaccination.
  • To provide administration guidelines and discuss implications for nursing practice.

Main Methods:

  • Comprehensive literature review of clinical trials on Varivax.
  • Analysis of vaccine efficacy, safety data, and economic projections.
  • Application of the Health Belief Model to a case study for administration guidelines.

Main Results:

  • Varivax is 95% to 100% effective in providing immunity for at least 10 years.
  • The vaccine is considered safe for administration in pediatric populations.
  • Precautions, contraindications, and administration guidelines are detailed.

Conclusions:

  • Varivax is a safe and effective option for preventing varicella in children.
  • Nurses play a crucial role in vaccine administration and patient education.
  • Further research is needed to explore long-term effectiveness and optimal use.

Related Concept Videos